What do recent large trials reveal about tirzepatide's cardiovascular benefits and safety in adults with type 2 diabetes and established cardiovascular disease or high cardiovascular risk?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: September 26, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Tirzepatide and Cardiovascular Outcomes: Recent Trial Evidence

Based on the most recent and highest-quality evidence, tirzepatide demonstrates cardiovascular safety and appears to reduce major adverse cardiovascular events (MACE) compared to both placebo proxies and active GLP-1 receptor agonist comparators in adults with type 2 diabetes and established cardiovascular disease. 1

Key Trial Findings

SURPASS-CVOT (2025): The Definitive Head-to-Head Comparison

The SURPASS-CVOT trial represents the most important recent evidence, directly comparing tirzepatide (up to 15 mg weekly) against dulaglutide (1.5 mg weekly) in 13,165 patients with type 2 diabetes and atherosclerotic cardiovascular disease 1. This was a double-blind, active-comparator trial—a critical design strength since dulaglutide itself has proven cardiovascular benefits.

Primary cardiovascular outcome (3-point MACE: cardiovascular death, MI, or stroke):

  • Tirzepatide: 12.2% of patients experienced events
  • Dulaglutide: 13.1% experienced events
  • Hazard ratio: 0.92 (95.3% CI: 0.83-1.01)
  • Result: Tirzepatide met noninferiority (p=0.003) but narrowly missed superiority (p=0.09) 1

This finding is clinically reassuring—tirzepatide is at minimum as safe as a proven cardiovascular-protective GLP-1 receptor agonist, with a strong trend toward superiority.

Expanded Cardiorenal Outcomes Analysis (2026)

A post-hoc analysis of SURPASS-CVOT examined a broader 6-component composite endpoint (all-cause mortality, MI, stroke, coronary revascularization, heart failure hospitalization, and kidney outcomes) 2:

  • Tirzepatide showed clear superiority: HR 0.84 (95% CI: 0.79-0.90; p<0.001)
  • 23.7% event rate with tirzepatide vs. 27.4% with dulaglutide
  • Number needed to treat: approximately 27 patients to prevent one event over median 47 months

Individual component benefits:

  • All-cause mortality: HR 0.69 (95% CI: 0.53-0.90) 3
  • Myocardial infarction: HR 0.70 (95% CI: 0.53-0.93) 3
  • Major adverse limb events: HR 0.59 (95% CI: 0.39-0.88) 3

The mortality benefit is particularly striking and clinically meaningful.

Real-World Evidence (2026)

A large population-based cohort study (52,971 participants) compared tirzepatide to sitagliptin (a cardiovascular-neutral comparator serving as placebo proxy) in patients with type 2 diabetes and established atherosclerotic cardiovascular disease 4:

One-year MACE risk:

  • Tirzepatide: 2.9% (95% CI: 2.5-3.4%)
  • Sitagliptin: 4.4% (95% CI: 3.8-4.9%)
  • Risk difference: -1.4% (NNT=70)
  • Hazard ratio: 0.68 (95% CI: 0.58-0.80)

This represents a 32% relative risk reduction in real-world practice—notably larger than the trial-based estimates, though the shorter follow-up and different comparator limit direct comparison.

Cardiovascular Safety in Earlier Disease Stages

The SURPASS-4 trial (2021) established cardiovascular safety in patients with type 2 diabetes at high cardiovascular risk (not necessarily established disease) 5:

  • MACE-4 events (CV death, MI, stroke, hospitalization for unstable angina): HR 0.74 (95% CI: 0.51-1.08)
  • Tirzepatide did not increase cardiovascular risk compared to insulin glargine
  • Lower hypoglycemia rates (6-9% vs. 19% with glargine)

Current Guideline Positioning

The 2025 American Association of Clinical Endocrinology consensus statement acknowledges that definitive cardiovascular outcome data for tirzepatide in type 2 diabetes is still emerging 6:

  • A prespecified post-hoc analysis showed tirzepatide did not increase MACE risk in participants with type 2 diabetes
  • The primary CVOT in individuals with type 2 diabetes is ongoing (SURPASS-CVOT, NCT04255433)—though we now have results showing noninferiority to dulaglutide
  • SURMOUNT-MMO is investigating both primary and secondary CV risk prevention in individuals with obesity without diabetes (NCT05556512)

The 2025 BMJ living guideline offers nuanced positioning 7:

  • Weak recommendation in favor of tirzepatide for adults with obesity
  • When choosing between GLP-1 receptor agonists and tirzepatide, clinicians should weigh the higher certainty of cardiovascular and kidney benefits (offered by GLP-1 receptor agonists) against larger weight loss benefits (offered by tirzepatide)
  • In adults at higher cardiovascular/kidney risk, tirzepatide should generally not replace medications effective in reducing these complications
  • If replacing a GLP-1 receptor agonist with tirzepatide, initiation or continuation of an SGLT-2 inhibitor is indicated

Clinical Decision-Making Algorithm

For patients with type 2 diabetes and established ASCVD:

  1. If already on dulaglutide or another proven GLP-1 receptor agonist: Consider continuing current therapy given established cardiovascular benefit, unless weight loss is inadequate and represents a major treatment goal. Tirzepatide offers similar cardiovascular safety with potentially greater weight reduction (12.8-14.7% vs. typical 5-10% with GLP-1 receptor agonists) 6, 8.

  2. If treatment-naive or on non-GLP-1 therapy: Tirzepatide is a reasonable first-line choice given:

    • Proven cardiovascular safety (noninferiority to dulaglutide)
    • Trend toward superiority on 3-point MACE
    • Clear superiority on broader cardiorenal composite
    • Superior glycemic control (A1C reduction 1.9-2.2%) 6
    • Superior weight loss (12.8-14.7% in patients with type 2 diabetes) 6

  3. Always ensure SGLT-2 inhibitor co-therapy in patients with established ASCVD or CKD, as these have the strongest cardiovascular and renal outcome data 7, 9.

Important Safety Considerations

Gastrointestinal adverse events are more common with tirzepatide:

  • Nausea: 12-23% (vs. 2% with glargine) 5
  • Diarrhea: 13-22% (vs. 4% with glargine) 5
  • Most cases are mild-to-moderate and occur during dose escalation 6

Discontinuation rates due to adverse events are consistently higher:

  • 32% increased risk of discontinuation vs. dulaglutide (RR 1.32,95% CI: 1.20-1.45) 10

Mitigation strategies 6:

  • Start at lowest dose (2.5 mg weekly) and titrate monthly
  • Avoid fatty foods, don't eat past fullness, eat smaller frequent meals
  • If treatment is paused, restart at low dose with gradual titration
  • Monitor for dehydration and renal impairment with vomiting/diarrhea

Other considerations:

  • Modest increase in heart rate 6
  • Increased gallbladder disease risk (common to all weight-loss therapies) 6
  • Lower hypoglycemia risk compared to insulin or sulfonylureas 6

Comparison to GLP-1 Receptor Agonists

Established GLP-1 receptor agonists with proven cardiovascular benefit include liraglutide (LEADER trial), semaglutide (SUSTAIN-6, SELECT trial), and dulaglutide (REWIND trial) 11, 6, 9, 12:

  • Liraglutide: 13% reduction in 3-point MACE (HR 0.87), significant reduction in CV death 13, 9
  • Semaglutide 2.4 mg: 20% reduction in 3-point MACE in SELECT trial (patients with obesity and established CVD, without diabetes) 6
  • Dulaglutide: Lower incidence of MACE-3 in REWIND trial 8

Tirzepatide's advantage lies primarily in:

  • Greater weight loss (15-20% vs. 5-10% with GLP-1 receptor agonists) 8
  • Superior glycemic control 6
  • Potentially broader cardiorenal benefits based on post-hoc analyses 2

GLP-1 receptor agonists maintain advantage in:

  • Longer track record of cardiovascular outcome data
  • Higher certainty evidence for cardiovascular death reduction (particularly liraglutide)
  • Potentially better tolerability/persistence 10

Bottom Line for Clinical Practice

Tirzepatide is cardiovascularly safe in patients with type 2 diabetes and established ASCVD, with emerging evidence suggesting potential cardiovascular benefit beyond what was initially demonstrated. The SURPASS-CVOT trial establishes noninferiority to dulaglutide for 3-point MACE, while post-hoc and real-world analyses suggest superiority for broader cardiorenal outcomes including all-cause mortality.

For patients prioritizing weight loss alongside cardiovascular protection, tirzepatide represents an excellent choice, provided gastrointestinal tolerability is managed proactively. For patients where treatment persistence is threatened by tolerability concerns, or where cardiovascular death reduction is the absolute priority based on longer-term outcome data, established GLP-1 receptor agonists (particularly liraglutide or semaglutide) remain appropriate alternatives. Regardless of choice, ensure SGLT-2 inhibitor co-therapy in high-risk patients for additive cardiovascular and renal protection.

References

6
Guideline

american association of clinical endocrinology consensus statement: algorithm for the evaluation and treatment of adults with obesity/adiposity-based chronic disease - 2025 update.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologist, 2025

Related Questions

Can tirzepatide be prescribed for a patient with stable coronary artery disease, and what is the recommended initiation and titration schedule?
What is the cardiovascular safety profile of tirzepatide?
Can tirzepatide be administered to an elderly patient with cardiac disease?
Can Mounjaro (tirzepatide) cause aggression, stress, anxiety, and stomach discomfort in a patient with a history of cardiovascular disease or type 2 diabetes, who is also taking Amlodipine (amlodipine besylate)?
What did the SURPASS trial demonstrate regarding major adverse cardiovascular events (MACE)?
What is the appropriate dosage adjustment of amoxicillin‑clavulanate (500 mg/125 mg) for an 86‑year‑old patient with a urinary tract infection and likely reduced renal function?
What is the onset time of prophylactic neuroprotective agents (e.g., dexamethasone) in spine surgery?
When should dexamethasone be given ideally to adult spine surgery patients?
Why do I have right-hand dexterity problems and a sensation of weakness and heaviness despite normal electromyography (EMG), nerve conduction studies (NCS), brain magnetic resonance imaging (MRI), and cervical spine MRI, with no progression over one year?
When is the appropriate time to obtain a repeat basic electrolyte panel after a dialysis session?
What does the presence of bilirubin in urine indicate and what initial evaluation is recommended?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.